These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34400802)

  • 21. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
    Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
    BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
    [No Abstract]   [Full Text] [Related]  

  • 22. Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic.
    Tsagakis I; Papatriantafyllou M
    Mol Oncol; 2020 Dec; 14(12):2987-2993. PubMed ID: 33128324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
    Martin T; Rioufol C; Favier B; Martelli N; Madelaine I; Chouaid C; Borget I
    BioDrugs; 2024 May; 38(3):465-475. PubMed ID: 38643301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 26. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 28. Keynote comment: Cancer drug pricing in the USA.
    Johnson DH
    Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent legislation changes the economics of cancer care.
    Silberman G; Downs CG
    ONS News; 2005 Jul; 20(7):9. PubMed ID: 16045235
    [No Abstract]   [Full Text] [Related]  

  • 30. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 31. Value-based payment models in oncology: will they help or hinder patient access to new treatments?
    Shah S; Reh G
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP188-SP190. PubMed ID: 28665677
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessing the pricing and benefits of oncology products: an update.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):335-342. PubMed ID: 33950772
    [No Abstract]   [Full Text] [Related]  

  • 33. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 34. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
    Fojo T; Grady C
    J Natl Cancer Inst; 2009 Aug; 101(15):1044-8. PubMed ID: 19564563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 37. Squaring value-based payment with innovation in oncology.
    Caffrey M
    Am J Manag Care; 2018 Oct; 24(12 Spec No.):SP482-SP484. PubMed ID: 30550253
    [No Abstract]   [Full Text] [Related]  

  • 38. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Letters to the Editors. Reflections about oncology. II. The reorganization of oncology -- solution or expansion of the problems?].
    Telekes A
    Orv Hetil; 2013 Jan; 154(2):76-9. PubMed ID: 23291207
    [No Abstract]   [Full Text] [Related]  

  • 40. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.